The risk of serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors decreased over time: a report from the registry of Japanese rheumatoid arthritis patients on biologics for long-term safety (REAL) database

Serious Infection ◽

Necrosis Factor ◽

Over Time

Long-Term Efficacy of Tumor Necrosis Factor Inhibitors for the Treatment of Methotrexate-Naïve Rheumatoid Arthritis: Systematic Literature Review and Meta-Analysis

Advances in Therapy ◽

10.1007/s12325-018-0869-8 ◽

2019 ◽

Vol 36 (3) ◽

pp. 721-745

Author(s):

László Gulácsi ◽

Zsombor Zrubka ◽

Valentin Brodszky ◽

Fanni Rencz ◽

Rieke Alten ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis Factor ◽

Literature Review ◽

Systematic Literature Review ◽

Tumor Necrosis ◽

Meta Analysis ◽

Term Efficacy ◽

The risk of serious infection in rheumatoid arthritis patients receiving tocilizumab compared with tumor necrosis factor inhibitors in Korea

Seminars in Arthritis and Rheumatism ◽

10.1016/j.semarthrit.2021.07.004 ◽

2021 ◽

Author(s):

Ha-Lim Jeon ◽

Seoyoung C. Kim ◽

So-Hee Park ◽

Ju-Young Shin

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Serious Infection ◽

Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry

Arthritis Research & Therapy ◽

10.1186/s13075-015-0583-8 ◽

2015 ◽

Vol 17 (1) ◽

Cited By ~ 33

Author(s):

Ryoko Sakai ◽

◽

Soo-Kyung Cho ◽

Toshihiro Nanki ◽

Kaori Watanabe ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Clinical Practice ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Risk of Serious Infection Among Initiators of Tumor Necrosis Factor Inhibitors Plus Methotrexate Versus Triple Therapy for Rheumatoid Arthritis: A Cohort Study

Arthritis Care & Research ◽

10.1002/acr.24038 ◽

2020 ◽

Vol 72 (10) ◽

pp. 1383-1391 ◽

Cited By ~ 2

Author(s):

Eun Ha Kang ◽

Yinzhu Jin ◽

Angela Y. Tong ◽

Rishi J. Desai ◽

Seoyoung C. Kim

Keyword(s):

Rheumatoid Arthritis ◽

Cohort Study ◽

Tumor Necrosis Factor ◽

Triple Therapy ◽

Tumor Necrosis ◽

Serious Infection ◽

Unaffected reaction level in tuberculin skin test by long-term therapy with tumor necrosis factor inhibitors for rheumatoid arthritis

International Journal of Rheumatic Diseases ◽

10.1111/1756-185x.13101 ◽

2017 ◽

Vol 20 (5) ◽

pp. 584-588

Author(s):

Shotaro Yamamoto ◽

Katsuya Nagatani ◽

Takeo Sato ◽

Masahiro Iwamoto ◽

Shino Takatori ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis Factor ◽

Tuberculin Skin Test ◽

Tumor Necrosis ◽

Term Therapy ◽

Long Term Therapy ◽

Necrosis Factor ◽

Reaction Level

AB1120 Comparison of Long-Term Drug Survival of Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis: A Single Center Turkish Experience Over a Decade

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2015-eular.5898 ◽

2015 ◽

Vol 74 (Suppl 2) ◽

pp. 1275.2-1276

Author(s):

G. Can ◽

S. Capar ◽

P. Cetin ◽

D. Solmaz ◽

G. Kenar ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Psoriatic Arthritis ◽

Ankylosing Spondylitis ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Single Center ◽

Drug Survival ◽

Long-term efficacy and safety of add-on tacrolimus for persistent, active rheumatoid arthritis despite treatment with methotrexate and tumor necrosis factor inhibitors

International Journal of Rheumatic Diseases ◽

10.1111/1756-185x.13248 ◽

2018 ◽

Vol 21 (3) ◽

pp. 673-687 ◽

Cited By ~ 3

Author(s):

Taio Naniwa ◽

Shiho Iwagaitsu ◽

Mikiko Kajiura

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Active Rheumatoid Arthritis ◽

Efficacy And Safety ◽

Term Efficacy ◽

The Effects of Tumor Necrosis Factor Inhibitors on Cardiovascular Risk in Rheumatoid Arthritis

Current Pharmaceutical Design ◽

10.2174/138161212799504786 ◽

2012 ◽

Vol 18 (11) ◽

pp. 1502-1511 ◽

Cited By ~ 24

Author(s):

Mike J.L. Peters ◽

Alper M. van Sijl ◽

Alexandre E. Voskuyl ◽

Naveed Sattar ◽

Yvo M. Smulders ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Cardiovascular Risk ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Miliary tuberculosis in a rheumatoid arthritis patient receiving long-term tumor necrosis factor monoclonal antibody therapy

Pulmonology ◽

10.1016/j.pulmoe.2021.01.010 ◽

2021 ◽

Author(s):

C.-R. Wang ◽

W.-C. Lin ◽

Y.-S. Tsai

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Rheumatoid Arthritis Patient ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Antibody Therapy ◽

Miliary Tuberculosis ◽

Monoclonal Antibody Therapy ◽

A Phase II Randomized Study of Subcutaneous Ixekizumab, an Anti-Interleukin-17 Monoclonal Antibody, in Rheumatoid Arthritis Patients Who Were Naive to Biologic Agents or Had an Inadequate Response to Tumor Necrosis Factor Inhibitors

Arthritis & Rheumatology ◽

10.1002/art.38617 ◽

2014 ◽

Vol 66 (7) ◽

pp. 1693-1704 ◽

Cited By ~ 137

Author(s):

Mark C. Genovese ◽

Maria Greenwald ◽

Chul-Soo Cho ◽

Alberto Berman ◽

Ling Jin ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Randomized Study ◽

Biologic Agents ◽

Interleukin 17 ◽

Inadequate Response ◽